Sup /fit/, Bryan Johnson's small molecule skill issues finally caught up to him in the form of some rando influencer who also has small molecule skill issues finally beating his biomarkers.

Meanwhile, we've got Chinese researchers dropping senolytic papers where a bunch of classically oncology-targeted protein pathways are being repurposed into osteoporosis research:
>The Role of Senolytics in Osteoporosis
>https://www.mdpi.com/2218-273X/15/8/1176
>We discussed major types of senolytics, such as natural compounds, kinase inhibitors, Bcl-2 family inhibitors, inhibitors of the mouse double minute 2/p53 interaction, heat shock protein 90 inhibitors, p53-binding inhibitors, and histone deacetylase inhibitors. This review also highlights the progress of senolytics in clinical trials. However, clinical results diverge from preclinical evidence. Therefore, senolytics should be critically evaluated as a potential therapeutic strategy for osteoporosis, with further validation required.

Of course, there is a lot more to proteome modulation than just senolytics or Yamanaka factors. Anyone else more advanced than DWS and Bryan Johnson looking at specific protein targets to delay/prevent age-related disease?

>>16753267
>>16753301
What proteins cause age-related disease burden and how you can reduce them prophylactically.
>protip: study SASP in biology context.